Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Clofarabine in the treatment of poor risk acute myeloid leukaemia.
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
MYC dysregulation in the progression of multiple myeloma.
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MYC dysregulation in the progression of multiple myeloma.
MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020 01; 34(1):322-326.
View in:
PubMed
subject areas
Disease Progression
Humans
Multiple Myeloma
Mutation
Proto-Oncogene Proteins c-myc
authors with profiles
Michael Joseph O'Dwyer